BioCentury | Jan 16, 2021
Product Development

Zymeworks showcases >45% confirmed ORRs for anti-HER2 bispecific in biliary, gastroesophageal cancers

Phase I data Zymeworks presented Friday for its bispecific anti-HER2 mAb back its ongoing and pending pivotal trials in biliary tract and gastroesophageal cancers, respectively. In an oral presentation at the American Society of Clinical Oncology...
BioCentury | Jan 15, 2021
Product Development

Readout for Arcus’ pancreatic cancer program could spur Gilead to exercise option

Early data showing clinical efficacy of a combination from Arcus in pancreatic cancer increases the likelihood that Gilead will exercise its option on the biotech’s potentially first-in-class molecule targeting CD73. An interim readout from the...
BioCentury | Jan 14, 2021

With €127M series B, cancer vaccine developer IO Biotech raises second-largest European venture round in the past year

IO Biotech parlayed early clinical data into a €127 million ($154.8 million) series B financing led by HBM Healthcare Investments, which will support a Phase II trial of its leading cancer vaccines in combination with...
BioCentury | Jan 12, 2021

Diverse syndicate stands behind EQRx’s mission with $500M series B round

EQRx is planning to deliver on its promise to provide equivalent or better low-cost drugs ahead of schedule with a $500 million series B, with diverse investor interest reflecting a mission that has only...
BioCentury | Jan 12, 2021

Novartis gains rights to BeiGene’s PD-1 in North America, Europe and Japan for $650M up front

After regaining worldwide rights to tislelizumab from Celgene Corp. in mid-2019, BeiGene has found a partner in major-market territories for the PD-1 inhibitor in Novartis, which paid $650 million up front on Monday for rights in...
BioCentury | Jan 12, 2021

Sanofi joins the myeloid checkpoint movement with Biond deal

Sanofi is staking claims in next-generation checkpoints through a new deal with Israeli biotech Biond around myeloid checkpoint target ILT2.  The deal with Biond Biologics Ltd., which gives the biotech $125 million up front and...
BioCentury | Jan 11, 2021

Atopic dermatitis readout drives Sanofi’s $1.1B takeout of Kymab

More than a decade after Kymab was first backed by the Wellcome Trust to derive drug candidates from an engineered mouse model, the company has accepted a $1.1 billion takeout offer from Sanofi that closely...
BioCentury | Jan 9, 2021

Targeted oncology is having a moment, again

The pandemic has only deepened the already heavily-weighted oncology focus of many portfolios, and it’s targeted oncology opportunities that are catching the eyes of buysiders in 2021. A combination of...
BioCentury | Dec 31, 2020

119 drugs added to China’s reimbursement list, which includes more domestic PD-1s

Negotiated additions to China’s National Reimbursement Drug List continue to drive down drug prices and expand access to checkpoint inhibitors, a category increasingly covered by domestic companies. Of the 162 drugs that underwent price negotiations,...
BioCentury | Dec 19, 2020
Product Development

Dec. 18 Quick Takes: FDA approves expanded label for Benlysta and first oral prostate cancer therapy; plus Novartis, FibroGen, A2i, China’s NRDL and more

FDA expands Benlysta label to include lupus nephritisFDA approved Benlysta belimumab from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) for adults with active lupus nephritis, making it the first therapy specifically approved for the systemic lupus erythematosus complication....
Items per page:
1 - 10 of 1464